MARKET WIREReuters • 46m ago
Iranians have left Doha talks, draft proposal for US deal being circulated, official says - ReutersIranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
Why TNYA Stock slipped -1.34% Today — RQD Quant Desk Flash
$0.40 -1.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.40
Tenaya Therapeutics Inc. (TNYA) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $90.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TNYA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TNYA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Tenaya Therapeutics Inc. (NASDAQ: TNYA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.40 (-1.34% 1D, market cap $90.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TNYA ranks #383 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TNYA compare to TVGN and ATRA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TNYA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TVGN (Tevogen Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $95.2M) and ATRA (Atara Biotherapeutics Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC 85.0%, cap $85.6M). Among the 5-stock peer group, TNYA leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TNYA?
▼
Per TNYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001858848), Tenaya Therapeutics Inc. generated $0 in revenue, -$90.6M in net income, and -$68.9M in free cash flow against $146.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.40 (-0.43%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TNYA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY TNYA SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (28% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$0.58-34.5% Next Q
54
Q2 (-2Q)Grade C-$0.38+2.6% Next Q
51
Q3 (-1Q)Grade D$0.39+2.6% Next Q
49
CurrentGrade D$0.40-6.1% Hist 90D α
46
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TNYA Turnaround Squeeze
While TNYA currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.57) and Max Pain ($0.42) forces dealer call-delta covering toward $1.64.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TNYA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TNYA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TNYA Stock slipped -1.34% Today — RQD Quant Desk Flash
Tenaya Therapeutics Inc. (TNYA) slipped -1.34% to $0.40, trading at 3% of its 52-week range ($0.36 – $1.56). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.36 – $1.56) with RSI-14 at 27.5 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.40 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TNYA Headlines & Catalysts
MARKET WIREReuters • 2h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
MARKET WIREReuters • 3h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 4h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 6h ago
Gold rises on softer oil; markets parse Fed signals - ReutersGold rises on softer oil; markets parse Fed signals Reuters
MARKET WIREReuters • 6h ago
China's Xi says Middle East should not become battleground for great power rivalry - ReutersChina's Xi says Middle East should not become battleground for great power rivalry Reuters
MARKET WIREReuters • 8h ago
Reliance earnings, lower oil prices power India's Sensex to near two-month high - ReutersReliance earnings, lower oil prices power India's Sensex to near two-month high Reuters
MARKET WIREReuters • 10h ago
Dollar pulls back ahead of US midterms; bitcoin stabilises after crypto heist - ReutersDollar pulls back ahead of US midterms; bitcoin stabilises after crypto heist Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TNYA)
- ✓Walkthrough of TNYA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TNYA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.03%▼ DESCENDING CHANNEL
2026-10-30O $0.39H $0.40L $0.37C $0.40VOL 2.66M
RES: $0.61SUP: $0.28SMA50: $0.57SMA200: $0.71
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TNYA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TNYA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TNYA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TNYA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TNYA)
Health Care Rank #383 of 1016
⚔️ TVGN vs TNYA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TNYA vs. TVGN, ATRA, ENGN, OKYO)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Tenaya Therapeutics Inc. (TNYA) ranks #383 by composite RQD confidence (46/100, grade D) and #675 by equity capitalization ($90.8M). Within this direct 5-issuer industry benchmark cohort, TNYA leads on earnings valuation at N/A trailing P/E, while ATRA leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. ATRA currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with TNYA at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TNYA
ACTIVE
Tenaya Therapeutics Inc. | D | 46/100 | — | — | -35.0% | -1.34% | $90.8M | Benchmark Subject |
| TVGN Tevogen Inc. | D- | 40/100 | — | — | -35.0% | -3.04% | $95.2M | /tvgn-vs-tnya → |
| ATRA Atara Biotherapeutics Inc. | D+ | 54/100 | — | — | 85.0% | -1.50% | $85.6M | /atra-vs-tnya → |
| ENGN enGene Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -3.16% | $102.5M | /engn-vs-tnya → |
| OKYO OKYO Pharma Limited | D+ | 52/100 | — | — | — | +0.67% | $78.7M | /okyo-vs-tnya → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001858848In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tenaya Therapeutics Inc. (TNYA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$90.6M, operating cash flow of -$68.3M, and free cash flow of -$68.9M (+24.7% YoY). On the balance sheet, TNYA closed FY2025 with $146.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$90.6M | -$68.3M | -$68.9M | $146.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$111.1M | -$90.5M | -$91.5M | $119.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$124.1M | -$102.1M | -$102.1M | — | — |
3. TNYA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TNYA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Tenaya Therapeutics Inc. (NASDAQ: TNYA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $0.40 (-1.34% 1D, market cap $90.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, TNYA ranks #383 in composite RQD confidence.
How does TNYA compare to TVGN and ATRA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TNYA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TVGN (Tevogen Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $95.2M) and ATRA (Atara Biotherapeutics Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC 85.0%, cap $85.6M). Among the 5-stock peer group, TNYA leads on earnings multiple (N/A) while ATRA leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TNYA?
Per TNYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001858848), Tenaya Therapeutics Inc. generated $0 in revenue, -$90.6M in net income, and -$68.9M in free cash flow against $146.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TNYA trading relative to its 50-day, 200-day, and 52-week technical levels?
TNYA last traded at $0.40 (-1.34% on volume of 1,779,362 shares), positioning the stock -29.82% below its 50-day simple moving average ($0.57) and -43.66% below its 200-day simple moving average ($0.71). Across its 52-week range of $0.36 to $1.56, TNYA sits at the 3.3% percentile with a 14-day RSI of 27.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.45).
TNYA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TNYA stock moving today?
Why TNYA Stock slipped -1.34% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.